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Pancreatic ductal adenocarcinoma has a median survival of less than 6 months from diagnosis. This is due to the difﬁculty in
early diagnosis, the aggressive biological behaviour of the tumour and a lack of effective therapies for advanced disease.
Mammalian heparanase is a heparan-sulphate proteoglycan cleaving enzyme. It helps to degrade the extracellular matrix and
basement membranes and is involved in angiogenesis. Degradation of extracellular matrix and basement membranes as well as
angiogenesis are key conditions for tumour cell spreading. Therefore, we have analysed the expression of heparanase in
human pancreatic cancer tissue and cell lines. Heparanase is expressed in cell lines derived from primary tumours as well as
from metastatic sites. By immunohistochemical analysis, it is preferentially expressed at the invading edge of a tumour at both
metastatic and primary tumour sites. There is a trend towards heparanase expression in metastasising tumours as compared
to locally growing tumours. Postoperative survival correlates inversely with heparanase expression of the tumour reﬂected by
a median survival of 34 and 17 month for heparanase negative and positive tumours, respectively. Our results suggest, that
heparanase promotes cancer cell invasion in pancreatic carcinoma and could be used as a prognostic indicator for
postoperative survival of patients.
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PDA has a poor prognosis due to its aggressive biological beha-
viour. In the majority of cases, diagnosis is only established late
in the course of the disease, when local invasive growth and distant
metastasis have already occurred (Baumel et al, 1994; Murr et al,
1994; Robert Koch Institut, 2002). At that point, the opportunity
for curative therapy, which is surgery at an early stage, has already
passed. Even though complete resection may still be achieved, the
rate of relapses is high (Connolly et al, 1987; Trede et al, 1990;
Cameron et al, 1991). Adjuvant combination therapy may offer a
small survival advantage but is associated with treatment related
morbidity. It therefore is not unequivocally accepted (Kalser and
Ellenberg, 1985; Ahlgren, 1996; Jeekel, 1997; Klinkenbijl et al,
1999). The cytotoxic agent gemcitabine is the only drug currently
known to be effective for palliation. Nevertheless, the absolute gain
in survival is marginal (Burris et al, 1997). A number of markers
have been associated with therapy-resistant tumours or shorter
survival. Their validity as prognostic criterion remains to be
conﬁrmed, though (Compton et al, 1997).
On the molecular level, several events including proto-oncogene
mutations such as K-ras (Almoguera et al, 1988), tumour suppres-
sor gene mutations in the p16INK4a, DPC4, and p53 genes
(Berrozpe et al, 1994; Caldas et al, 1994; Redston et al, 1994;
Schutte et al, 1997; Goggins et al, 1998), and overexpression of a
variety of growth factors and their receptors (Korc, 1998) have
been described in the carcinogenesis of pancreatic cancer. The
underlying causes for the aggressiveness of this cancer are still
not fully understood.
Invasion of tumour cells into the surrounding tissue requires
loosening of cell–cell adhesion, invasion of the basement
membrane and disassembly of the extracellular matrix. Chief
components of basement membrane (BM) and extracellular matrix
(ECM) such as collagens, ﬁbronectin and laminin are substrates of
metalloproteinases and cysteine and serine proteases, which are
known to be upregulated in metastatic cancers (Chambers and
Matrisian, 1997).
Recently, another ECM degrading enzyme, mammalian hepara-
nase, has been cloned from human placenta tissue and platelets
and a putative 65 kDa precursor and a 50 kDa recombinant active
enzyme have been expressed. Preliminary results suggest that
heparanase may be a cell membrane protein (Hulett et al, 1999;
Vlodavsky et al, 1999). The enzyme cleaves another key component
of BM and ECM, namely heparan sulphate proteoglycans (HSPG)
which belong to the glycosaminoglycans. Heparanase expression
and function may be regulated at the transcriptional and posttran-
scriptional level (Gilat et al, 1995; Andela et al, 2000), though this
topic awaits further clariﬁcation.
In addition to the enzymatic degradation of the ECM hepara-
nase acts by releasing growth factors such as bFGF, heparan
sulphate (HS) fragments and other enzymes such as lipoprotein
lipase from the ECM. Consistent with its molecular capabilities
heparanase has been shown to stimulate wound healing and
tumour angiogenesis in vivo (Elkin et al, 2001). Its expression is
upregulated in a number of metastatic tumour cell lines and
transfection of tumour cells with heparanase cDNA conferred a
highly metastatic phenotype (Hulett et al, 1999; Vlodavsky et al,
1999).
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www.bjcancer.comHeparanase expression has been studied in human primary
tumours and tumour cell lines. Its expression correlates with
tumour progression and invasiveness in colorectal and hepatocellu-
lar carcinoma (Friedmann et al, 2000; El-Assal et al, 2001). In this
study, we examined the expression of heparanase protein and
mRNA in human PDA cell lines and tumours. In addition, we
studied the correlation of heparanase expression and stage of
disease with postoperative survival in the intent to identify putative
prognostic markers.
MATERIALS AND METHODS
Cell Culture and DNA transfection
Eight pancreatic cancer cell lines (AsPC-1, BxPC-3, Capan-1, Hs
766T, PANC-1, HPAF-II, CFPAC, MIA PaCa-2), the colorectal
cancer cell line HT29 and the cervical cancer cell line HeLa
were obtained from American Type Culture Collection (Mana-
ssas, USA) and maintained in the recommended growth
conditions. Transfection for overexpression of Heparanase in
HeLa cells was performed on cells growing at *70% conﬂu-
ence in T75 plates, using full-length Heparanase cDNA in
pcDNA3 (Vlodavsky et al, 1999) and FuGENE 6 transfection
reagent (Roche, Germany) according to the manufacturer’s
instruction.
RNA-isolation and semiquantitative RT–PCR
RNA was isolated from cell lines with the RNeasy Kit (Qiagen,
Germany) according to the manufacturer’s instructions. After
reverse transcription of 5 mg total RNA by oligo(dT) priming
(Superscript, Invitrogen, USA), the resulting cDNA was ampliﬁed
by PCR using Taq DNA polymerase (Qiagen, Germany) and the
heparanase primers 5'-GTGATGAGGCAAGTATTCTTTGG and
5'-TC AGATGCAAGCAGCAACTTTG. The PCR conditions were
an initial denaturation of 5 min at 948C and subsequent dena-
turation for 30 s at 948C, annealing for 30 s at 588C and
extension for 1 min at 728C (26 cycles). Standard b-actin
primers and identical PCR conditions were used as internal input
controls. PCR products were separated by 1.5% agarose gel elec-
trophoresis and visualised by SYBR Green staining (Biozym
Diagnostik, Germany).
Western blot analysis
Cells were dissolved in lysis buffer containing 5 M NaCl, 10%
NP-40 (Igepal CA-630, Sigma-Aldrich, Germany), 1 M TRIS
pH 8 and protease inhibitors (Complete Mini, EDTA free, Roche,
Germany) at 48C for 45 min and centrifuged at 13000 r.p.m. for
20 min. The protein concentration of the supernatant was
measured by the Bradford assay (BioRad, USA). 50 mg of each
protein was separated by electrophoresis on 10% SDS/polyacryla-
mide gels and transferred to Hybond-P-Membrane (Amersham
Pharmacia Biotech, UK) by semidry electroblotting (Transblot,
BioRad, USA). Western blot analysis was carried out with a
mouse monoclonal anti-heparanase antibody as previously
described (Vlodavsky et al, 1999). A monoclonal antibody against
b-actin (Sigma-Aldrich, USA) was used to verify equal loading of
western blots. The secondary antibody used was a horseradish-
peroxidase-conjugated goat-anti-mouse antibody (Pierce, USA).
Immunoreactive bands were detected by enhanced chemilumines-
cence (SuperSignal, Pierce, USA) and exposure in a luminescent
image analyser (LAS-1000plus, FujiFilm, USA).
Patients and tissue samples
Tissue specimens were chosen from 25 patients with chronic
pancreatitis, from 50 patients with ductal adenocarcinoma of the
pancreas undergoing surgery of curative intent between 1995 and
1999 and from ﬁve cases with normal pancreatic tissue. The
PDA patients included 26 patients, in whom the tumours were
R0 resected. Each tumour was re-evaluated with regard to typing,
staging and grading. Tumour typing and staging were performed
using WHO (Klo ¨ppel et al, 2000) and UICC (Sobin and Wittekind,
1997) criteria.
Immunohistochemistry
2–4mm sections of formaline-ﬁxed and parafﬁn-embedded speci-
mens were deparafﬁnised and rehydrated. Endogenous peroxidase
was blocked by 3% H2O2. Tissue was then demethylated in a
microwave oven, incubated with citrate buffer, and blocked with
goat serum. Sections were incubated with the monoclonal anti
human heparanase antibody (Vlodavsky et al, 1999) or with non-
immune mouse serum for negative control, respectively. Following
washes with PBS sections were incubated with biotinylated goat
anti-mouse IgG+IgM antibodies (BioGenex, USA), rinsed with
PBS and incubated with peroxidase-labelled streptavidin. Colour
was developed using Sigma Fast 3,3'-Diaminobenzidine (Sigma-
Aldrich, USA). Counterstaining was performed with Mayer’s hema-
toxylin. Samples were evaluated by microscopy and
semiquantitavely analysed for heparanase expression (intense,
moderate or absent staining).
Riboprobe preparation and in situ hybridisation
A 482 bp fragment of the human heparanase cDNA (primers iden-
tical to RT–PCR primers) was subcloned into the pGEMT vector
multiple cloning site (Promega, USA). The linearized vector was
used as a template for in vitro transcription and digoxigenin label-
ing of antisense or sense riboprobe using SP6 and T7-RNA
polymerase (Roche, Germany). In situ hybridisation was performed
as described before (Vlodavsky et al, 1999; Friedmann et al, 2000).
Brieﬂy, 5 mm sections were dewaxed and rehydrated, denaturated
with 0.2 N HCl for 10 min and then digested with proteinase K
(200 mgm l
71)a t3 7 8C for 30 min. Digestion was stopped with
two changes of H2O. Slides were prehybridised and hybridised as
described (Vlodavsky et al, 1999; Friedmann et al, 2000). Probe
concentration was 2 mgm l
71. Washes after hybridisation, incuba-
tion with anti-digoxigenin antibodies, and calorimetric detection
were performed as described before (Vlodavsky et al, 1999; Fried-
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Table 1 Clinical and histological characteristics of 50 patients with pan-
creatic cancers
Heparanase expression Yes (%) No (%) Chi square
UICC stage
I 4 (80) 1 (20)
II 5 (59) 5 (50) P=0.17
III 23 (85) 4 (15) n.s.
IV 6 (75) 2 (25)
Lymph node metastasis
No 11 (61) 7 (39) P=0.06
Yes 27 (84) 5 (16) n.s.
Distant metastasis
No 32 (76) 10 (24) n.s.
Yes 6 (75) 2 (25)
Grading
1 2 (100) 0 (0) P=0.61
2 27 (77) 8 (23) n.s.
3 9 (69) 4 (31)
Correlation analysis of heparanase expression (total positive=38, total negative=12)
with staging (UICC), lymph node and distant metastases and histological grading (1
well, 2 moderately, 3 poorly differentiated carcinoma) by Chi square test.
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Mayer’s hematoxylin.
Statistical analysis
Fisher’s exact test was used to calculate the signiﬁcance levels of
contingency tables for differences of Heparanse expression regard-
ing UICC stage, lymph node metastasis, distant metastasis or
grading. For patients with R0 resected tumours postoperative survi-
val periods were computed by the Kaplan–Meier method and
compared by the Log Rank test. A P-value 50.05 was considered
signiﬁcant. SPSS-statistical software (SPSS), version 10, was used
for data analysis.
RESULTS
Heparanase expression in human pancreatic cancer cell
lines
We examined eight human pancreatic cancer cell lines from differ-
ent tissues of origin for the expression of heparanase mRNA and
protein. Four of the cell lines (CFPAC, AsPC-1, HPAF-II, Hs
766T) had been established from distant metastases (liver, ascites)
and lymph node metastases, respectively. Heparanase was expressed
in all cell lines, but could hardly be detected in two cell lines
(BxPC-3, Hs 766T) as determined by Western blot (Figure 1A).
The level of expression varied widely. Apparently, heparanase
expression did not correlate with whether or not the cell line
was derived from a metastatic site. We also looked for levels of
mRNA expression by quantitative RT–PCR. Levels of mRNA
correlated closely with protein expression in the tumour cell lines
examined (Figure 1B).
Heparanase expression in human pancreatic cancer tissue
We analysed sections of tumour tissue from 50 patients (mean age
63 years, range 41–77 years, 27 male/23 female) that were operated
on for pancreatic cancer and from 25 patients with chronic
pancreatitis. Of the 50 tumour patients, 26 underwent a potentially
curative resection, whereas the remaining 24 had microscopic
evidence of non-curative resection (R1 resection). By immunohis-
tochemical analysis, there was no detectable heparanase
expression in normal pancreatic tissue. In contrast, heparanase
showed high, moderate, or no expression in 17, 22, and 11 tumour
specimens, respectively. Heparanase was preferentially expressed at
the invading edge of PDA, though there was also some level of
expression in the surrounding inﬂamed tissue (Figure 2). The level
of expression was higher in primary tumours than at metastatic
sites. Heparanase was shown to be moderately expressed in chronic
pancreatitis. In situ hybridisation demonstrated, that the mRNA
expression pattern followed closely that of protein expression.
There was no correlation between UICC stage of disease and
heparanase expression. In contrast, there was a trend towards
heparanase expression in lymph node positive vs negative tumours
(P=0.064) (Table 1 and Figure 3).
Heparanase expression and postoperative survival of
patients
In the intent to determine the prognostic value of heparanase in
pancreatic cancer, we have analysed heparanase expression, stage
of disease and survival of those 26 patients, that had been cura-
tively resected (R0 resection). There was a signiﬁcant negative
correlation between postoperative survival and heparanase expres-
sion (Figure 4) (P50.01). Mean postoperative survival was 34
months and 17 month in heparanase negative and positive
tumours (R0 resection), respectively. Survival of patients with
tumours expressing high or moderate levels of heparanase did
not differ signiﬁcantly. Multivariate analysis could not establish
heparanase expression as an independent prognostic factor due
to a lack of statistical power. There was no correlation between
UICC stage of disease and postoperative survival in this series (data
not shown).
DISCUSSION
PDA is characterised by its local invasive growth including invasion
of the perineurium and by a high frequency of metastases. In our
study, heparanase was expressed in the majority of tumour speci-
mens and expression at the invading edge of tumours could be
demonstrated. This ﬁnding underscores the potential role of hepar-
anase in tumour invasion and may partly explain the aggressiveness
of PDA. We could conﬁrm previous results that heparanase expres-
sion levels are higher at the primary tumour site than at metastatic
sites (Koliopanos et al, 2001). This possibly reﬂects the need to
break down physiological restraints like BM and ECM before a
tumour cell can metastasise. How expression of heparanase is
downregulated once a cell has settled at its metastatic site is still
unresolved. In light of the results of other studies of heparanase
expression in various tumours (Friedmann et al, 2000; El-Assal et
al, 2001; Ginath et al, 2001) heparanase activation appears to be
a crucial step for a tumour to become systemic.
Therapeutic options in PDA are scarce. There is no established
adjuvant therapy after successfull operation despite the fact that
the disease frequently relapses. Palliative treatments apart from best
supportive care offer only marginal improvements in quality of life
and survival, if any (Ahlgren, 1996; Burris et al, 1997; Jeekel, 1997).
Therefore, it would be helpful to identify patients that might bene-
ﬁt from adjuvant therapy. We found that patients with heparanase
expressing PDA had a signiﬁcantly shorter postoperative survival
than patients with no heparanase expression. In contrast, neither
stage of disease nor lymph node involvement predicted prognosis,
although this may be due to the small study size. Our ﬁnding is in
agreement with previously published results (Koliopanos et al,
2001). We have to caution, though, that the number of patients
in our study precluded a multivariate analysis. Prospective studies
could lend further support to our ﬁnding. The relatively long post-
operative survival periods in our study are probably due to a
positive selection of patients whose tumours were deemed to be
resectable preoperatively.
An important question is how heparanase expression and func-
tion are regulated under different physiological and
pathophysiological conditions. Clues to physiological mechanisms
may be infered from the role of heparanase in pregnancy, morpho-
genesis and development (Dempsey et al, 2000; Goldshmidt et al,
2001). Heparanase expression is also evident in inﬂammation,
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Figure 1 (A) Western blot analysis of heparanase expression in the hu-
man pancreatic cancer cell lines (AsPC-1 [4], BxPC-3 [5], Capan-1 [6],
CFPAC [7], HPAF-II [8], Hs 766T [9], MIA PaCa-2 [10] and PANC-1
[11]). The colorectal cancer cell line HT-29 [1] and the cervical cancer cell
line HeLa transfected with heparanase cDNA were used as positive con-
trols. Untransfected HeLa cells were used as negative control [3]. b-Actin
Western blot to conﬁrm equal protein loading. (B) Semiquantitative RT–
PCR of heparanase mRNA in human pancreatic cancer cell lines. DNA lad-
der [1], water control [2], AsPC-1 [3], BxPC-3 [4], Capan-1 [5], CFPAC [6],
HPAF-II [7], Hs 766T [8], MIA PaCa-2 [9] and PANC-1 [10].
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2001). Heparanase is expressed by a variety of cell types and helps
the cells to cross physiological boundaries, as is the case with
trophoblasts in the placenta, leukocyte extravasation, or tumour
cell metastasis (Parish et al, 2001). There are as yet few identiﬁed
molecular mechanisms of heparanase regulation. These comprise
transcriptional and posttranscriptional mechanisms such as
tissue-pH and regulation by NF-kB and proto-oncogenes (Schwarz
et al, 1990; Gilat et al, 1995; Andela et al, 2000). In our study
expression of heparanase mRNA and protein in vivo showed signif-
icant overlap. Transcriptional upregulation therefore appears to be
the main way of PDA cells to beneﬁt from the prometastatic and
angiogenic effects of heparanase.
The key role of heparanase in tumorigenesis and the existing
evidence for only one endogenous mammalian heparan sulphate
degrading endoglycosidase (Hulett et al, 1999; Vlodavsky et al,
1999) has spurred efforts to develop therapeutic applications. So
far, non-anticoagulant heparins and sulphated oligosaccharides
show promising results in animal studies of tumour spreading
(Miao et al, 1999; Parish et al, 1999). A drug of the latter group,
Phosphomannopentaose sulfate (PI-88), slowed tumour growth
and metastasis and reduced the vascularity of tumours both in vitro
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Figure 2 Heparanase expression and localisation in primary human pancreatic cancers (A,D,G), chronic pancreatitis (B,E) and histologically normal pan-
creas (C,F). HE staining (A,B,C) for histological evaluation. Immunohistochemical staining with a monoclonal a-heparanase Ab and in situ hybridisation with
an antisense (G) and sense probe (H, negative control). Normal pancreas with absent (F) and chronic pancreatitis with moderate (E) heparanase expres-
sion. Carcinoma tissue with strong heparanase expression (D,G), or absent heparanase expression (M). Heparanase positive tumour cells invading lymph
sheets (I). Lymph node metastasis with strong (K) or absent heparanase expression (I).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1270–1275and in vivo in animals (Parish et al, 1999). Hopefully, this and
other studies will emerge into clinical trials of the most promising
of these drugs.
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Figure 3 Heparanase expression in pancreatic cancers depending on
lymph node metastasis (n=32) vs absent metastasis (n=18).
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Figure 4 Survival curves of 26 pancreatic cancer patients with R0 resec-
tion. Kaplan–Meier plots of postoperative survival curves of patients with
or without heparanase expression in the primary carcinoma. Log-rank
analysis proves a shorter postoperative survival period for patients with
heparanase expression in their tumours (P50.01).
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